In vitro, 4F-PCC failed to normalize thrombin generation at FXa inhibitor concentrations ≥75 ng/mL, whereas andexanet normalized it across a wide range of concentrations (19-2000 ng/mL).
Does 4F-PCC improve thrombin generation in human plasma treated with factor Xa inhibitors compared to andexanet alfa?
In an in vitro model, andexanet alfa effectively reversed factor Xa inhibitors over a wide concentration range, whereas 4F-PCCs only normalized thrombin generation at very low inhibitor concentrations (<75 ng/mL).
BACKGROUND: Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for anticoagulation reversal in patients with life-threatening bleeding treated with rivaroxaban or apixaban. Four-factor prothrombin complex concentrates (4F-PCCs) are approved for reversal of vitamin K antagonist-induced anticoagulation but not FXa inhibitors. The mechanism and effectiveness of 4F-PCCs for FXa inhibitor reversal are unclear. OBJECTIVE: To investigate the mechanism and impact of 4F-PCCs on reversal of rivaroxaban and apixaban in vitro compared to andexanet. METHODS: The effect of 4F-PCCs (or individual factors) on tissue factor-initiated thrombin generation (TF-TG) was evaluated in human plasma, with or without rivaroxaban or apixaban, and compared with andexanet under the same conditions. RESULTS: In the TF-TG assay, 4F-PCC completely reversed warfarin anticoagulation. Andexanet normalized TF-TG over a wide range of apixaban and rivaroxaban concentrations tested (19-2000 ng/mL). However, 4F-PCC (or individual factors) was unable to normalize endogenous thrombin potential (ETP) or peak thrombin (Peak) in the presence of apixaban or rivaroxaban (75-500 ng/mL). TF-TG was only normalized by 4F-PCC at inhibitor concentrations <75 ng/mL (ETP) or <37.5 ng/mL (Peak). These data can be explained by the estimated thresholds of FXa activity required to support normal TF-TG based on the inhibitor:FXa ratios and levels of uninhibited FXa. The data are consistent with healthy volunteer studies where TF-TG is not normalized until inhibitor levels are substantially decreased. CONCLUSIONS: Both the theoretical calculations and experimental data demonstrated that 4F-PCCs are only able to normalize TG over a low and narrow range of FXa inhibitor concentrations (<75 ng/mL).
Lu et al. (Thu,) conducted a other in Anticoagulation reversal. 4F-PCC vs. Andexanet alfa was evaluated on Tissue factor-initiated thrombin generation (TF-TG). In vitro, 4F-PCC failed to normalize thrombin generation at FXa inhibitor concentrations ≥75 ng/mL, whereas andexanet normalized it across a wide range of concentrations (19-2000 ng/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: